A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology

Biomedical Papers

Volumn 159, Issue 4, 2015, Pages 519-526

  Mihaila, Romeo Gabriel ^a  

^a LUCIAN BLAGA UNIVERSITY OF SIBIU   (Romania)

Author keywords

Amiloride; Apoptosis; BCR ABL; Cariporide; FLT3 ITD; Heme oxygenase 1; Imatinib mesylate; Intracellular pH; Isoprenylation; Leukemia; Lovastatin; Na+ H+ exchanger; P glycoprotein; Sorafenib; Statins

Indexed keywords

AMILORIDE; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CARIPORIDE; CATION TRANSPORT PROTEIN; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; GUANIDINE DERIVATIVE; HEME OXYGENASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; SLC9A1 PROTEIN, HUMAN; SODIUM PROTON EXCHANGE PROTEIN; SORAFENIB; SULFONE;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DNA DAMAGE; DRUG EFFECTS; DRUG INTERACTION; GENETICS; HUMAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MUTATION; ONCOGENE; OSMOLARITY; PATENT; PH; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR HYPOXIA; UPREGULATION;

AMILORIDE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; DNA DAMAGE; DRUG INTERACTIONS; FMS-LIKE TYROSINE KINASE 3; GENES, ABL; GUANIDINES; HEME OXYGENASE-1; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MUTATION; NIACINAMIDE; OSMOLAR CONCENTRATION; PATENTS AS TOPIC; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SODIUM-HYDROGEN ANTIPORTER; SULFONES; TUMOR HYPOXIA; UP-REGULATION;

EID: 84949681281     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2015.060     Document Type: Review

References (43)

1. Hrgovic I, Glavic Z, Kovacic Z, Mulic S, Zunic L, Hrgovic Z. Repeated administration of inhibitors for ion pumps reduce markedly tumor growth in vivo. Med Arch 2014;68(2):76-8.
2. Spugnini EP, Sonveaux P, Stock C, Perez-Sayans M, De Milito A, Avnet S, Garcìa AG, Harguindey S, Fais S. Proton channels and exchangers in cancer. Biochim Biophys Acta 2014;184810 Pt B:2715-26.
3. Daniel C, Bell C, Burton C, Harguindey S, Reshkin SJ, Rauch C. The role of proton dynamics in the development and maintenance of multi-drug resistance in cancer. Biochim Biophys Acta 2013;1832(5):606-17.
4. Rich IN, Worthington-White D, Garden OA, Musk P. Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na(+)/H(+) exchanger. Blood 2000;95(4):1427-34.
5. + exchanger. Can J Physiol Pharmacol 2006 Nov;84(11):1081-95.
6. + exchanger, pH regulation and cancer. Recent Pat Anticancer Drug Discov 2013;8(1):85-99.
7. Harguindey S, Arranz JL, Polo Orozco JD, Rauch C, Fais S, Cardone RA, Reshkin SJ. Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs--an integral molecular/ biochemical/metabolic/clinical approach after one hundred years of cancer research. J Transl Med 2013;11:282.
8. Reshkin SJ, Bellizzi A, Caldeira S, Albarani V, Malanchi I, Poignee M, Alunni-Fabbroni M, Casavola V, Tommasino M. Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB 2000;14(14):2185-97.
9. Mirossay A, Mirossay L, Sarisský M, Papp P, Mojzis J. Modulation of the phototoxic effect of hypericin in human leukemia CEM cell line by N-ethylmaleimide, amiloride and omeprazole. Physiol Res 2002;51(6):641-4.
10. + exchanger. Physiol Res 1999;48(2):135-41.
11. Man CH, Lam SS, Sun MK, Chow HC, Gill H, Kwong YL, Leung AY. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML. Blood 2014;123(16):2530-9.
12. Jin W, Li Q, Lin Y, Lu Y, Li H, Wang L, Hu R, Ma L, Wang J, Pang T. Reversal of Imatinib resistance in BCR-ABL-positive leukemia after inhibition of the Na+/H+ exchanger. Cancer Lett 2011;308(1):81-90.
13. Affar el B, Shah RG, Dallaire AK, Castonguay V, Shah GM. Role of poly(ADP-ribose) polymerase in rapid intracellular acidification induced by alkylating DNA damage. Proc Natl Acad Sci U S A 2002;99(1):245-50.
14. + exchanger 1 to mediate K562 chronic myeloid leukemia cells' differentiation via ERK1/2 signaling pathway. Leuk Res 2014;38(9):1117-25.
15. Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle 2009;8(8):1168-75.
16. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J. ERK2, but not ERK1, induces epithelial to mesenchymal transformation via DEF motif dependent signaling events. Mol Cell 2010;38(1):114-27.
17. Garden OA, Musk P, Worthington-White DA, Dewey MJ, Rich IN. Silent polymorphisms within the coding region of human sodium/hydrogen exchanger isoform-1 cDNA in peripheral blood mononuclear cells of leukemia patients: A comparison with healthy controls. Cancer Genet Cytogenet 2000;120(1):37-43.
18. Hallows KR, Restrepo D, Knauf PA. Control of intracellular pH during regulatory volume decrease in HL-60 cells. Am J Physiol 1994;267(4 Pt 1):C1057-66.
19. Jin W, Li Q, Wang J, Chang G, Lin Y, Li H, Wang L, Gao W, Pang T. Na+/ H+ exchanger 1 inhibition contributes to K562 leukaemic cell differentiation. Cell Biol Int 2012;36(8):739-45.
20. Jin WN, Wang J, Chang GQ, Lin YN, Wang LH, Li HW, Gao W, Li QH, Pang TX. Inhibition of NHE1 promotes hypoxia-induced differentiation of K562 leukemic cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011;19(3):661-5.
21. Zhao R, Oxley D, Smith TS, Follows GA, Green AR, Alexander DR. DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. PLoS Biol 2007;5(1):e1.
22. Zhao R, Follows GA, Beer PA, Scott LM, Huntly BJ, Green AR, Alexander DR. Inhibition of the Bcl-xL deamidation pathway in my-eloproliferative disorders. Engl J Med 2008;359(26):2778-89.
23. (+) exchanger. Blood 2000;95(4):1427-34.
24. (+) exchanger. European Journal of Medicinal Chemistry 2003;38(6):547-54.
25. Chang WH, Liu TC, Yang WK, Lee CC, Lin YH, Chen TY, Chang JG. Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib. Cancer Res 2011;71(2):383-92.
26. Gao W, Zhang H, Chang G, Xie Z, Wang H, Ma L, Han Z, Li Q, Pang T. Decreased intracellular pH induced by cariporide differentially contributes to human umbilical cord-derived mesenchymal stem cells differentiation. Cell Physiol Biochem 2014;33(1):185-94.
27. Li H, Chang G, Wang J, Wang L, Jin W, Lin Y, Yan Y, Wang R, Gao W, Ma L, Li Q, Pang T. Cariporide sensitizes leukemic cells to tumor necrosis factor related apoptosis-inducing ligand by up-regulation of death receptor 5 via endoplasmic reticulum stress-CCAAT/enhancer binding protein homologous protein dependent mechanism. Leuk Lymphoma 2014;55(9):2135-40.
28. + exchanger inhibitor cariporide through down-regulation of pro-angiogenesis factor VEGF. Leuk Res 2011;35(11):1506-11.
29. Pérez-Sala D, Collado-Escobar D, Mollinedo F. Intracellular alkalinization suppresses lovastatin-induced apoptosis in HL-60 cells through the inactivation of a pH-dependent endonuclease. J Biol Chem 1995;270(11):6235-42.
30. Clark SS, Perman SM, Sahin MB, Jenkins GJ, Elegbede JA. Antileukemia activity of perillyl alcohol (POH): uncoupling apoptosis from G0/G1 arrest suggests that the primary effect of POH on Bcr/Abl-transformed cells is to induce growth arrest. Leukemia 2002;16(2):213-22.
31. Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia- Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer 2014;120(14):2142-9.
32. + exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells. Biol Chem 2015;290(20):12558-71.
33. Hu RH, Jin WN, Chang GQ, Lin YN, Wang J, Ru YX, Li QH, Pang TX. Increasing sensitivity of leukemia cells to imatinib by inhibiting NHE1 and p38MAPK signaling pathway. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012;20(6):1341-5.
34. Li QH, Lu Y, Jin WN, Lin YN, Hu RH, Zhu XF, Wang JX, Pang TX. Effect of intracellular acidification on drug resistance of leukemia cells with high P-glycoprotein expression. Zhonghua Xue Ye Xue Za Zhi 2009;30(9):605-9.
35. Sih HJ, Stolen C, Ou J, Wagner DO. Methods to position therapeutic agents using a magnetic field. US 20080006281 (2008).
36. Wishart N, Argiriadi MA, Calderwood DJ, Ericsson AM, Fiamengo BA, Frank KE, Friedman MM, George DM, Goedken ER, Josephsohn NS, Li BC, Stewart KD, Wallace GA, Wang L, Woller KR. Tricyclic compounds. US 20090312338 (2009).
37. Wishart N, Frank KE, Friedman M, George DM, Stewart KD, Wallace GA. Tricyclic compounds. US 20110311474 (2011).
38. Watterson DM, Van Eldik LJ. Protein kinase targeted therapeutics. US 20110166153 (2011).
39. Ghayur T, Salfeld JG, McPherson MJ. Dual variable domain immuno-globulins and uses thereof. US 20120087858 (2012).
40. Rogers RD, Daly DT, Swatloski RP, Hough-Troutman WL, Davis JH, Smiglak M, Pernak J, Spear SK. Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients. US 20120264605 (2012).
41. Wan MM, Avgerinos G, Zarbis-Papastoitsi G. Purified antibody composition. US 20130273059 (2013).
42. Meyer MD, Wang X, Guo T, Wei RGP, Wang LJ. Chemokine receptor antagonists. US 20130261129 (2013).
43. Neely LA, Audeh MJ, Blanco M, Chepin JF, Demas V, Dhanda RK, Lowery TJ. NMR systems and methods for the rapid detection of analytes. US 20130266944 (2013).